[go: up one dir, main page]

DK0779284T3 - Hidtil ukendte 2-naphtanamidderivater og terapeutiske anvendelser heraf som agonister af D3-receptorer - Google Patents

Hidtil ukendte 2-naphtanamidderivater og terapeutiske anvendelser heraf som agonister af D3-receptorer

Info

Publication number
DK0779284T3
DK0779284T3 DK96402672T DK96402672T DK0779284T3 DK 0779284 T3 DK0779284 T3 DK 0779284T3 DK 96402672 T DK96402672 T DK 96402672T DK 96402672 T DK96402672 T DK 96402672T DK 0779284 T3 DK0779284 T3 DK 0779284T3
Authority
DK
Denmark
Prior art keywords
derivatives
agonists
naphtanamide
receptors
novel
Prior art date
Application number
DK96402672T
Other languages
English (en)
Inventor
Andre Mann
Camille-Georges Wermuth
Fabrice Garrido
Jeanne-Marie Lecomte
Jean-Charles Schwartz
Pierre Sokoloff
Original Assignee
Ile Bioprojet Soc Civ
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ile Bioprojet Soc Civ, Inst Nat Sante Rech Med filed Critical Ile Bioprojet Soc Civ
Application granted granted Critical
Publication of DK0779284T3 publication Critical patent/DK0779284T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
DK96402672T 1995-12-11 1996-12-09 Hidtil ukendte 2-naphtanamidderivater og terapeutiske anvendelser heraf som agonister af D3-receptorer DK0779284T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9514654A FR2742149B1 (fr) 1995-12-11 1995-12-11 Nouveaux derives de 2-naphtamides et leurs applications therapeutiques

Publications (1)

Publication Number Publication Date
DK0779284T3 true DK0779284T3 (da) 2002-10-07

Family

ID=9485370

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96402672T DK0779284T3 (da) 1995-12-11 1996-12-09 Hidtil ukendte 2-naphtanamidderivater og terapeutiske anvendelser heraf som agonister af D3-receptorer

Country Status (11)

Country Link
US (2) US5872119A (da)
EP (1) EP0779284B1 (da)
JP (1) JPH09291033A (da)
KR (1) KR100447033B1 (da)
AT (1) ATE220399T1 (da)
CA (1) CA2192535C (da)
DE (1) DE69622246T2 (da)
DK (1) DK0779284T3 (da)
ES (1) ES2179919T3 (da)
FR (1) FR2742149B1 (da)
PT (1) PT779284E (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19600934A1 (de) 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
WO1998037893A1 (en) * 1997-02-26 1998-09-03 Sumitomo Pharmaceuticals Co., Ltd. Dopamine d4 receptor antagonist
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
AR022228A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para la preparar dicha composicion
JP2003513053A (ja) * 1999-11-04 2003-04-08 アボット ゲーエムベーハー ウント カンパニー カーゲー 塩依存性高血圧症の治療におけるドーパミンｄ３受容体アゴニストの使用
US20030087917A1 (en) * 2000-03-27 2003-05-08 Dorothea Strack Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system
US20020103198A1 (en) * 2000-12-04 2002-08-01 Fliri Anton F.J Acylamino cyclopropane derivatives
EP1260221A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination treatment for depression and anxiety
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
EP1509213A2 (en) * 2002-05-23 2005-03-02 Abbott Laboratories Acetamides and benzamides that are useful in treating sexual dysfunction
DE10232020A1 (de) 2002-07-04 2004-02-26 Friedrich-Alexander-Universität Erlangen-Nürnberg Neurorezeptoraktive Heteroarencarboxamide
WO2005051940A2 (en) * 2003-11-20 2005-06-09 Eli Lilly And Company Vitamin d receptor modulators
EP1683790A1 (en) * 2005-01-24 2006-07-26 Institut National De La Sante Et De La Recherche Medicale (Inserm) 3,4-dihydro-2-naphthamide derivatives as selective dopamine D3 ligands
CN1948298B (zh) * 2006-11-09 2010-09-01 东南大学 一种多巴胺d3受体部分激动剂及其应用
WO2010040274A1 (zh) 2008-10-10 2010-04-15 中国人民解放军军事医学科学院毒物药物研究所 新型多巴胺d3受体配体，其制备方法及其医药用途
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
CN105294685B (zh) * 2015-11-23 2017-03-08 东南大学 六氢吡嗪并喹啉类d3受体配体及其制备方法和用途
CN105461608B (zh) * 2015-11-23 2017-11-28 东南大学 二氢吲哚‑2‑酮类d3受体配体及其制备方法和用途
JP7017797B2 (ja) * 2017-02-24 2022-02-09 深▲チェン▼市霊蘭生物医薬科技有限公司 新規なドーパミンｄ３受容体選択的リガンド及びびその調製方法並びに医薬使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4975439A (en) * 1987-09-25 1990-12-04 Janssen Pharmaceutical N.V. Novel substituted N-(1-alkyl-3-hydroxy-4-piperidinyl)benzamides
US5106849A (en) * 1988-05-24 1992-04-21 American Home Products Corporation Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders
US5010078A (en) * 1988-05-24 1991-04-23 American Home Products Corporation Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity
US5254552A (en) * 1988-05-24 1993-10-19 American Home Products Corporation Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity
FR2682953B1 (fr) * 1991-10-23 1995-04-21 Inst Nat Sante Rech Med Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique.
SE9201138D0 (sv) * 1992-04-09 1992-04-09 Astra Ab Novel phthalimidoalkylpiperazines
WO1993023035A2 (en) * 1992-05-18 1993-11-25 Smithkline Beecham Plc Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease
US5395835A (en) * 1994-03-24 1995-03-07 Warner-Lambert Company Naphthalamides as central nervous system agents
DE69534213T2 (de) * 1994-10-25 2006-01-12 Astrazeneca Ab Therapeutisch wirksame Heterocyclen

Also Published As

Publication number Publication date
CA2192535C (fr) 2006-05-16
JPH09291033A (ja) 1997-11-11
KR970042506A (ko) 1997-07-24
EP0779284B1 (fr) 2002-07-10
US5985895A (en) 1999-11-16
EP0779284A1 (fr) 1997-06-18
FR2742149A1 (fr) 1997-06-13
CA2192535A1 (fr) 1997-06-12
DE69622246D1 (de) 2002-08-14
ES2179919T3 (es) 2003-02-01
US5872119A (en) 1999-02-16
KR100447033B1 (ko) 2004-11-03
FR2742149B1 (fr) 1998-02-13
DE69622246T2 (de) 2002-11-07
PT779284E (pt) 2002-11-29
ATE220399T1 (de) 2002-07-15

Similar Documents

Publication Publication Date Title
DK0779284T3 (da) Hidtil ukendte 2-naphtanamidderivater og terapeutiske anvendelser heraf som agonister af D3-receptorer
MY119150A (en) Azetidine derivatives, their preparation and medicaments containing them
DK0590919T3 (da) Terapeutiske midler mod Parkinsons sygdom
DK1235776T3 (da) Triphenylalkenderivater og deres anvendelse som selektive östrogenreceptormodulatorer
PE20010009A1 (es) Derivados de fenil - y piridinilo como antagonistas del receptor de la neuroquinina 1
HUP0105079A2 (hu) Indolszármazékok és felhasználásuk MCP-1 antagonistákként, eljárás a vegyületek előállítására és ezeket tartalmazó gyógyszerkészítmények
ATE182591T1 (de) 5-ht4 rezeptor antagonisten
DK0562956T3 (da) Hidtil ukendte naphthylalkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
NO20045486L (no) Nye forbindelser og deres anvendelse
ES2092639T3 (es) Mejoras en o relativas a antagonistas de receptores de aminoacidos excitatorios.
DE69433984D1 (de) Arylpiperazinderivate von indol als liganden der rezeptoren 5 ht1-like, 5 ht1b und 5 ht1d
FI870347A0 (fi) Nya dihydrobensofuran- och kromankarboxiamidderivat, foerfarande foer deras framstaellning och deras anvaendning som neuroleptiska medel.
ES2191341T3 (es) Derivados de la 2-fenoxianilina.
NO178397C (no) Substituerte 1,2,3,4-tetrahydrocyklopent[bÅindoler, 1,2,3,3a,4,8a-heksahydrocyklopent[bÅindoler og beslektede forbindelser, mellomprodukter og deres bruk som medikamenter
JO2235B1 (en) Derivatives of phenyl
DK0648202T3 (da) Substituerede (arylalkylaminobenzyl)aminopropanamidderivater, fremstilling deraf og anvendelse som anti-epileptiske, neurobeskyttende og antidepressive midler
DK0885004T3 (da) Anvendelse af 4-phenyl-3,6-dihydro-2H-pyridyl-derivater som NMDA-receptor-undertypeblokkere
FI950209A0 (fi) Farmakologisesti aktiiviset alfa-(tertiaarinen-amino-metyyli)-bentseenimetanolijohdannaiset
IT1313583B1 (it) Derivati 2-amminotetralinici per la terapia del glaucoma.
BG106079A (en) Cyclocarbamate derivatives as progesterone receptor modulators
AR005613A1 (es) Empleo de los derivados de la tetrahidroisoquinolina
ATE203533T1 (de) INDOLDERIVATE ALS PRODRUGS VON ß5-HT1-LIKEß REZEPTOR AGONISTEN
ES2119454T3 (es) Derivados de pirrolidina para el tratamiento de los desordenes relacionados con la csk y la gastrina.
TH28860A (th) สารประกอบชนิดใหม่
TH20641A (th) 6-[ไทรแอโซลิล[3-(ไทรฟลูออโรเมธิล)เฟนิล]เมธิล]-2-ควิโนลิโนนและ-ควิโนลีนไธโอน